Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cancer and Stem Cell Research

Executive Summary: Y-27632 dihydrochloride is a highly selective inhibitor of Rho-associated protein kinases (ROCK1 and ROCK2), with IC₅₀ values of approximately 140 nM for ROCK1 and a K_i of 300 nM for ROCK2, demonstrating over 200-fold selectivity against other kinases (APExBIO, product page). It modulates cell proliferation, cytoskeletal reorganization, stress fiber formation, and cytokinesis in a concentration-dependent manner (Luo et al., 2021). Y-27632 enhances stem cell viability and facilitates the establishment of organoid cultures. Its solubility profile supports versatile experimental designs. APExBIO provides the A3008 kit for reproducible research outcomes.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases involved in key cellular processes, including actin cytoskeleton regulation, cell cycle progression, and cytokinesis. Dysregulation of ROCK signaling is implicated in tumor invasion, metastasis, and abnormal cell proliferation (Luo et al., 2021). Selective ROCK inhibitors, such as Y-27632 dihydrochloride, enable targeted interrogation of these pathways. By inhibiting Rho-mediated contractility and stress fiber formation, Y-27632 serves as a critical tool in cancer biology, regenerative medicine, and stem cell research.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride inhibits the catalytic domains of ROCK1 and ROCK2. The compound binds competitively at ATP-binding sites, impeding kinase activity with an IC₅₀ of ~140 nM for ROCK1 and a K_i of 300 nM for ROCK2 (APExBIO product page). Y-27632 exhibits >200-fold selectivity over kinases such as PKC, cAMP-dependent protein kinase, MLCK, and PAK. Inhibition of ROCK signaling leads to disruption of actin stress fibers, reduced cellular contractility, and impaired cytokinesis. This results in altered cell morphology, decreased cell proliferation, and modulation of the G1 to S phase cell cycle transition. The compound is cell-permeable and active in both in vitro and in vivo contexts.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM under standard kinase assay conditions (APExBIO, product page).
• It demonstrates over 200-fold selectivity against PKC, cAMP-dependent protein kinase, MLCK, and PAK in competitive kinase assays (APExBIO, product page).
• The compound disrupts Rho-mediated formation of stress fibers and focal adhesions in cultured cells (APExBIO, product page).
• In vitro, Y-27632 reduces proliferation of primary prostatic smooth muscle cells in a dose-dependent fashion (APExBIO, product page).
• In vivo mouse models show that Y-27632 suppresses tumor invasion and pathological structure formation (Luo et al., 2021).
• Y-27632 enables efficient establishment and maintenance of patient-derived breast cancer organoids, supporting translational research (Luo et al., 2021).

For a comparative guide on experimental workflows and troubleshooting with Y-27632, see Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Cytoskeletal Research—this article builds upon those workflows by providing updated selectivity and in vivo evidence. For in-depth discussion of epithelial morphogenesis and stem cell regulation, consult Y-27632 Dihydrochloride: Advanced ROCK Inhibition in Epithelial Biology, which this article augments with quantitative solubility and storage data. For translational perspectives in immuno-oncology, see Y-27632 Dihydrochloride: Unveiling ROCK Inhibition in Tumor Immunology, while this dossier focuses on reproducibility and protocol integration.

Applications, Limits & Misconceptions

Applications:

• Cancer Research: Inhibits tumor cell invasion, metastasis, and proliferation in preclinical models.
• Stem Cell Biology: Enhances viability and expansion of pluripotent stem cells and supports organoid establishment.
• Cytoskeletal Studies: Disrupts actin stress fiber formation, enabling precise analysis of Rho/ROCK signaling.
• Cell Proliferation Assays: Used to modulate cell cycle progression and cytokinesis in various cell types.
• Organoid Culture: Essential for robust establishment of patient-derived 3D cultures (Luo et al., 2021).

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor; its selectivity for ROCK1/2 is >200-fold compared to other kinases.
• Long-term storage of Y-27632 solutions at room temperature can result in degradation; solid form should be stored desiccated at 4°C or below.
• The compound does not reverse established fibrosis or metastatic disease in vivo; its effects are context and timing dependent.
• Y-27632 does not induce pluripotency; it maintains stem cell viability but does not reprogram somatic cells.
• Not suitable for direct clinical administration; for research use only.

Workflow Integration & Parameters

Y-27632 dihydrochloride (APExBIO A3008) is provided as a solid, to be dissolved prior to use. Solubility is ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water. Dissolution can be facilitated by warming to 37°C or ultrasonic bath treatment. Stock solutions should be stored below -20°C and used within several months for best results. Avoid repeated freeze-thaw cycles. The recommended working concentration range is 1–10 μM for in vitro assays. For organoid culture, concentrations of 10 μM have been shown to enhance viability and establishment rates (Luo et al., 2021). For detailed experimental protocols, refer to the official product page.

Conclusion & Outlook

Y-27632 dihydrochloride is a validated, highly selective ROCK1/2 inhibitor supporting reproducible research in cancer biology, stem cell expansion, and cytoskeletal modulation. Its robust solubility and storage parameters make it adaptable to diverse workflows. APExBIO's A3008 kit enables standardized application in translational studies. Ongoing research continues to expand the applications of Y-27632, particularly in advanced organoid models and precision oncology. For further strategic guidance on Rho/ROCK pathway modulation, see Precision Modulation of Rho/ROCK Signaling—this dossier adds stability data and critical application boundaries beyond the mechanistic focus of previous reviews.